Bank of New York Mellon’s Collegium Pharmaceutical COLL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.51M | Buy |
234,960
+9,255
| +4% | +$316K | ﹤0.01% | 2117 |
|
|
2026
Q1 | $7.46M | Sell |
225,705
-1,414
| -0.6% | -$59.9K | ﹤0.01% | 2085 |
|
|
2025
Q4 | $10.5M | Sell |
227,119
-21,855
| -9% | -$914K | ﹤0.01% | 1899 |
|
|
2025
Q3 | $8.71M | Sell |
248,974
-901
| -0.4% | -$31.3K | ﹤0.01% | 2009 |
|
|
2025
Q2 | $7.39M | Buy |
249,875
+7,614
| +3% | +$217K | ﹤0.01% | 2052 |
|
|
2025
Q1 | $7.23M | Sell |
242,261
-10,426
| -4% | -$319K | ﹤0.01% | 2021 |
|
|
2024
Q4 | $7.24M | Sell |
252,687
-11,763
| -4% | -$389K | ﹤0.01% | 2095 |
|
|
2024
Q3 | $10.2M | Sell |
264,450
-32,280
| -11% | -$1.15M | ﹤0.01% | 1914 |
|
|
2024
Q2 | $9.55M | Sell |
296,730
-10,901
| -4% | -$378K | ﹤0.01% | 1982 |
|
|
2024
Q1 | $11.9M | Sell |
307,631
-15,021
| -5% | -$526K | ﹤0.01% | 1874 |
|
|
2023
Q4 | $9.93M | Buy |
322,652
+11,416
| +4% | +$286K | ﹤0.01% | 1992 |
|
|
2023
Q3 | $6.96M | Sell |
311,236
-9,136
| -3% | -$208K | ﹤0.01% | 2153 |
|
|
2023
Q2 | $6.88M | Sell |
320,372
-5,424
| -2% | -$123K | ﹤0.01% | 2144 |
|
|
2023
Q1 | $7.82M | Buy |
325,796
+812
| +0.2% | +$21.5K | ﹤0.01% | 2053 |
|
|
2022
Q4 | $7.54M | Sell |
324,984
-35,470
| -10% | -$715K | ﹤0.01% | 2097 |
|
|
2022
Q3 | $5.77M | Sell |
360,454
-2,189
| -0.6% | -$38.6K | ﹤0.01% | 2222 |
|
|
2022
Q2 | $6.43M | Sell |
362,643
-25,009
| -6% | -$421K | ﹤0.01% | 2182 |
|
|
2022
Q1 | $7.89M | Sell |
387,652
-10,880
| -3% | -$206K | ﹤0.01% | 2202 |
|
|
2021
Q4 | $7.45M | Buy |
398,532
+29,705
| +8% | +$579K | ﹤0.01% | 2258 |
|
|
2021
Q3 | $7.28M | Buy |
368,827
+5,345
| +1% | +$116K | ﹤0.01% | 2299 |
|
|
2021
Q2 | $8.59M | Sell |
363,482
-28,105
| -7% | -$649K | ﹤0.01% | 2231 |
|
|
2021
Q1 | $9.28M | Buy |
391,587
+198,329
| +103% | +$4.71M | ﹤0.01% | 2121 |
|
|
2020
Q4 | $3.87M | Buy |
193,258
+9,726
| +5% | +$190K | ﹤0.01% | 2483 |
|
|
2020
Q3 | $3.82M | Sell |
183,532
-4,573
| -2% | -$82.5K | ﹤0.01% | 2358 |
|
|
2020
Q2 | $3.29M | Buy |
188,105
+2,013
| +1% | +$39.4K | ﹤0.01% | 2420 |
|
|
2020
Q1 | $3.04M | Sell |
186,092
-7,273
| -4% | -$150K | ﹤0.01% | 2321 |
|
|
2019
Q4 | $3.98M | Sell |
193,365
-196
| -0.1% | -$3.27K | ﹤0.01% | 2444 |
|
|
2019
Q3 | $2.22M | Buy |
193,561
+4,018
| +2% | +$45.9K | ﹤0.01% | 2701 |
|
|
2019
Q2 | $2.49M | Buy |
189,543
+4,524
| +2% | +$60.5K | ﹤0.01% | 2682 |
|
|
2019
Q1 | $2.8M | Sell |
185,019
-2,628
| -1% | -$42.1K | ﹤0.01% | 2610 |
|
|
2018
Q4 | $3.22M | Sell |
187,647
-9,521
| -5% | -$163K | ﹤0.01% | 2508 |
|
|
2018
Q3 | $2.91M | Sell |
197,168
-40,857
| -17% | -$724K | ﹤0.01% | 2656 |
|
|
2018
Q2 | $5.68M | Sell |
238,025
-48,073
| -17% | -$1.18M | ﹤0.01% | 2325 |
|
|
2018
Q1 | $7.31M | Buy |
286,098
+61,726
| +28% | +$1.47M | ﹤0.01% | 2153 |
|
|
2017
Q4 | $4.14M | Buy |
224,372
+119,640
| +114% | +$1.71M | ﹤0.01% | 2446 |
|
|
2017
Q3 | $1.1M | Sell |
104,732
-229
| -0.2% | -$2.52K | ﹤0.01% | 3166 |
|
|
2017
Q2 | $1.31M | Buy |
104,961
+39,656
| +61% | +$392K | ﹤0.01% | 3091 |
|
|
2017
Q1 | $656K | Buy |
65,305
+3,775
| +6% | +$56.1K | ﹤0.01% | 3446 |
|
|
2016
Q4 | $958K | Buy |
61,530
+9,630
| +19% | +$160K | ﹤0.01% | 3281 |
|
|
2016
Q3 | $999K | Sell |
51,900
-221,081
| -81% | -$2.63M | ﹤0.01% | 3175 |
|
|
2016
Q2 | $3.23M | Sell |
272,981
-64,642
| -19% | -$1.07M | ﹤0.01% | 2448 |
|
|
2016
Q1 | $6.13M | Buy |
337,623
+310,731
| +1,155% | +$5.65M | ﹤0.01% | 2080 |
|
|
2015
Q4 | $739K | Hold |
26,892
| – | – | ﹤0.01% | 3343 |
|
|
2015
Q3 | $594K | Buy |
26,892
+3,118
| +13% | +$56.4K | ﹤0.01% | 3506 |
|
|
2015
Q2 | $424K | Buy |
+23,774
| New | +$411K | ﹤0.01% | 3691 |
|
Other funds holding COLL
Bank of New York Mellon's COLL Position: Q2 2026 in Review
Bank of New York Mellon increased its Collegium Pharmaceutical (COLL) stake by 4.1% in Q2 2026, buying an estimated $316K and bringing the position to 234,960 shares worth $8.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2117.
Bank of New York Mellon first reported a position in COLL in Q2 2015 and has held it in 45 quarters since. The position peaked at $11.9M in Q1 2024. 156 funds tracked by Wall St. Rank hold COLL as of Q2 2026.
- Bank of New York Mellon held 234,960 shares of Collegium Pharmaceutical worth $8.51M as of Q2 2026.
- Bank of New York Mellon bought 9,255 Collegium Pharmaceutical shares in Q2 2026, an estimated $316K.
- Collegium Pharmaceutical made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2117 holding.
- Bank of New York Mellon first reported a position in Collegium Pharmaceutical in Q2 2015 and has held it in 45 quarters since.
- Bank of New York Mellon's Collegium Pharmaceutical position peaked at $11.9M in Q1 2024.
- 156 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.